Stephan Kloss
Overview
Explore the profile of Stephan Kloss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schultze-Florey C, Thol F, Aleksandrova K, Stoyanov K, Gutierrez Jauregui R, Arseniev L, et al.
Leukemia
. 2025 Mar;
PMID: 40057635
No abstract available.
2.
Walcher L, Kistenmacher A, Sommer C, Bohlen S, Ziemann C, Dehmel S, et al.
Front Immunol
. 2021 Jun;
12:684052.
PMID: 34149724
Background: With increasing clinical use of NK-92 cells and their CAR-modified derivatives in cancer immunotherapy, there is a growing demand for efficient production processes of these "off-the-shelf" therapeutics. In order...
3.
Dragon A, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Kloss S, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33127653
Background: Immunosuppressive therapy or T-cell depletion in transplant patients can cause uncontrolled growth of Epstein-Barr virus (EBV)-infected B cells resulting in post-transplant lymphoproliferative disease (PTLD). Current treatment options do not...
4.
Kloss S, Dehmel S, Braun A, Parnham M, Kohl U, Schiffmann S
Front Immunol
. 2020 Aug;
11:1423.
PMID: 32733473
Success in cancer treatment over the last four decades has ranged from improvements in classical drug therapy to immune oncology. Anti-cancer drugs have also often proven beneficial for the treatment...
5.
Bursch F, Rath K, Sarikidi A, Boselt S, Kefalakes E, Osmanovic A, et al.
J Tissue Eng Regen Med
. 2019 Feb;
13(4):649-663.
PMID: 30811816
Cellular therapy represents a novel option for the treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). Its major aim is the generation of a protective environment for degenerating...
6.
Volk V, Reppas A, Robert P, Spineli L, Sundarasetty B, Theobald S, et al.
Front Immunol
. 2017 Dec;
8:1709.
PMID: 29276513
Mice transplanted with human cord blood-derived hematopoietic stem cells (HSCs) became a powerful experimental tool for studying the heterogeneity of human immune reconstitution and immune responses . Yet, analyses of...
7.
Kloss S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, et al.
Hum Gene Ther
. 2017 Aug;
28(10):897-913.
PMID: 28810809
The administration of ex vivo expanded natural killer (NK) cells as potential antitumor effector cells appears to be suitable for effector cell-based immunotherapies in high-risk cancer patients. However, good manufacturing...
8.
Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhoff B, et al.
Front Immunol
. 2016 Oct;
7:393.
PMID: 27746781
Background And Aims: The infusion of enriched CMV-specific donor T-cells appears to be a suitable alternative for the treatment of drug-resistant CMV reactivation or infection after both solid organ and...
9.
Roemer A, Kohl U, Majdani O, Kloss S, Falk C, Haumann S, et al.
Stem Cell Res Ther
. 2016 Oct;
7(1):148.
PMID: 27717379
Background: The success of cochlear implantation may be further improved by minimizing implantation trauma. The physical trauma of implantation and subsequent immunological sequelae can affect residual hearing and the viability...
10.
Kloss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, et al.
Front Immunol
. 2015 Nov;
6:543.
PMID: 26579120
Immunosuppressive factors, such as soluble major histocompatibility complex class I chain-related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1), are involved in tumor immune escape mechanisms (TIEMs) exhibited...